Randomized Adjuvant Trial of Tamoxifen and Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil: Evidence for the Superiority of Treatment With Endocrine Blockade in Premenopausal Patients With Hormone-Responsive Breast Cancer—Austrian Breast and Colorectal Cancer Study Group Trial 5

Jakesz, R.; Hausmaninger, H.; Kubista, E.; Gnant, Michael; Menzel, Christian; Bauernhofer, Thomas; Seifert, Michael; Haider, Karin; Mlineritsch, Brigitte; Steindorfer, P.; Kwasny, Werner; Fridrik, Michael A.; Steger, Guenther G.; Wette, Viktor; Samonigg, Hellmut

doi:10.1200/jco.2002.09.112

Cited by 256 publications

(135 citation statements)

References 24 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…22 In addition, the results from several large, randomized trials recently have confirmed the role of Gn-RH analogues in the adjuvant treatment of early breast carcinoma either as monotherapy 23 or in combination with tamoxifen and/or chemotherapy. 24,25 In particular, the Zoladex Early Breast Cancer Research Association trial, which compared the efficacy and tolerability of goserelin with that of CMF, after a median follow-up of 7.3 years, showed equivalence between goserelin and CMF for disease-free survival and overall survival in patients with ER positive disease and demonstrated the superiority of CMF for both disease-free survival and overall survival compared with goserelin in patients who had ER-negative tumors. 25 Because of the presence of several heterogeneous cell populations in the same breast carcinoma, theoretically, neither ovarian ablation nor chemotherapy is capable of eradicating all cell clones that compose a tumor.…”

Section: Discussionmentioning

confidence: 99%

Gonadotropin‐releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma

Recchia

Saggio

Amiconi

et al. 2005

Cancer

120

View full text Add to dashboard Cite

BACKGROUND The objective of the current study was a retrospective evaluation of 100 consecutive premenopausal women with high‐risk, early breast carcinoma who received a gonadotropin‐releasing hormone (Gn‐RH) analogue as ovarian protection during adjuvant chemotherapy. METHODS After surgery, patients received a Gn‐RH analogue and adjuvant chemotherapy, which was tailored to their peculiar biologic features. The median patient age was 43 years (range, 27–50 yrs). Fifty‐two women had positive estrogen receptor (ER) status, and 48 women had negative ER status. There were 64 women with Stage II breast carcinoma and 36 women with UICC Stage III breast carcinoma. All patients had their serum estradiol suppressed to values < 40 pg/mL. The chemotherapy regimens administered included cyclophosphamide, methotrexate, and 5‐fluorouracil (n = 26 patients) and anthracycline‐based regimens (n = 74 patients, including 9 patients who had > 10 positive axillary lymph nodes, who also received high‐dose chemotherapy with autologous peripheral blood progenitor cell transplantation). Patients with positive c‐erb‐2 status also received a taxane. Eighty patients received radiation therapy. During therapy with the Gn‐RH analogue, patients who had a positive ER status after chemotherapy received an aromatase inhibitor. RESULTS After a median follow‐up of 75 months, normal menses were resumed by all patients younger than age 40 years and by 56% of patients older than age 40 years. Three pregnancies were observed that resulted in two normal deliveries and one voluntary abortion. The projected recurrence‐free survival rates at 5 years and 10 years were 84% and 76%, respectively; and the projected overall survival rates at 5 years and 10 years were 96% and 91%, respectively. CONCLUSIONS The current data showed that, in premenopausal women with early breast carcinoma, the addition of a Gn‐RH analogue to adjuvant therapy and temporary total estrogen suppression in patients with ER‐positive disease was tolerated well, protected long‐term ovarian function, and appeared to improve the expected clinical outcome. Cancer 2006. © 2005 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

Gonadotropin‐releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma

Recchia

Saggio

Amiconi

et al. 2005

Cancer

120

View full text Add to dashboard Cite

show abstract

“…All patients had participated in either ABCSG Trial 05 or ABCSG Trial 06 and have received tamoxifen as part of their adjuvant treatment. Inclusion criteria and the main clinical results of both studies have been reported previously (23,24).…”

Section: Methodsmentioning

confidence: 99%

Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy

Rudas

Lehnert²,

Huynh³

et al. 2008

Clinical Cancer Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…Ovarian suppression has been under investigation in place of or in addition to adjuvant chemotherapy for young patients with newly diagnosed hormone-sensitive, early stage breast cancer [52][53][54]. In a large study comparing Sonmezer,Oktay 425 www.TheOncologist.com the efficacy and tolerability of monthly goserelin treatment for 2 years (n = 817) with CMF (n = 823), goserelin produced a similar DFS to that seen with CMF in estrogen receptor-positive patients after a median follow-up of 6 years [55].…”

Section: Use Of Nongonadotoxic Ovarian Suppression Regimens As Adjuvamentioning

confidence: 99%

Fertility Preservation in Young Women Undergoing Breast Cancer Therapy

2006

View full text Add to dashboard Cite

show abstract

Randomized Adjuvant Trial of Tamoxifen and Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil: Evidence for the Superiority of Treatment With Endocrine Blockade in Premenopausal Patients With Hormone-Responsive Breast Cancer—Austrian Breast and Colorectal Cancer Study Group Trial 5

Abstract: Overall, our data suggest that the goserelin-tamoxifen combination is significantly more effective than CMF in the adjuvant treatment of premenopausal patients with stage I and II breast cancer.

Cited by 256 publications

References 24 publications

Gonadotropin‐releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma

Gonadotropin‐releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma

Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy

Fertility Preservation in Young Women Undergoing Breast Cancer Therapy

Contact Info

Product

Resources

About